Hyderabad, India, September 22, 2016: UL Compliance to Performance (UL), a division of global safety science company UL, entered into an Alliance Agreement with PharmExcil, to be their Knowledge Partner. UL Compliance to Performance helps life sciences clients achieve results in three core areas: Compliance, Quality, and Performance.  This is done through complete advisory, software, and learning solutions addressing client needs from the early stages of new market entry, through scale-up, and continuing operations and supply chain management.

As part of the agreement, UL Compliance to Performance will conduct domestic and international seminars, workshops and / or webinars on topics including but not limited to Regulatory Training on cGMP, SOP Management, Good Clinical Practices, Data Integrity, CAPA, Validations and Inspection Readiness.

The Alliance Agreement makes UL the Knowledge Partner and Subject Matter Experts (SME) at PharmExcil educational events based on mutual agreement between UL and PharmExcil including topics on Market Entry, Regulatory Compliance, Quality and Business Performance in the Medical Device and Pharmaceutical industry.

On this momentous occasion, Isabelle Noblanc, Vice President and General Manager, UL Compliance to Performance, Princeton NJ, USA, said “UL Compliance to Performance is delighted to partner with PharmExcil to help the pharmaceutical industry drive high business performance while achieving anytime compliance with international regulations.  Our global experience, life sciences focus, and partnerships with several international regulatory agencies allow us to support an industry that surmounts challenges such as rapid scale up, stringent and rapidly evolving regulations, and competing in a constantly changing global market.”

Suresh Sugavanam, VP & MD, South Asia, UL said, “We believe that the partnership is an endorsement to the quality of work UL has been delivering over the last few years. The alliance provides UL with the opportunity to contribute and participate in the quality and safety assurance initiatives of the pharmaceutical industry in India, which is now going through a major transition in terms of the quality demands of the international regulatory agencies.”

On this occasion Dr PV Appaji, Director General, PharmExcil stated, “With the pharmaceutical sector in India being the largest producer of cost effective generic medicines for developed countries, gaining expertise in regulatory compliance mechanisms from across the world will only consolidate our export potential. Collaborating with a reputed safety science company like UL will bring to the fore the latest and best practices in pharmaceutical quality and safety, thereby enabling Indian pharma companies to navigate complex regulatory requirements around the globe and achieve wider global market access.”

About PharmExcil:

PharmExcil is set up by the Ministry of Commerce & Industry, Government of India under the Foreign Trade Policy for promotion of pharmaceutical exports from India through facilitation of trade delegations, buyer-seller meetings, international seminars. PharmExcil is administered by Committee of Administration consisting of representatives from major pharmaceutical companies in India.

About UL:

UL is a premier global independent safety science company that has championed progress for more than 120 years. Its nearly 11,000 professionals are guided by the UL mission to promote safe working and living environments for all people. UL uses research and standards to continually advance and meet ever-evolving safety needs. We partner with businesses, manufacturers, trade associations and international regulatory authorities to bring solutions to a more complex global supply chain. For more information about our certification, testing, inspection, advisory and education services, visit www.ul.com